[New epileptic treatments. Current modalities and their utilization]

Area of Science:

• Pharmacology and Neurology
• Drug Development and Therapeutics

Context:

• Since 1990, nine novel antiepileptic drugs (AEDs) have been introduced in France.
• These new AEDs initially addressed cases of insufficient efficacy or intolerance to older generations of antiepileptic medications.
• The therapeutic landscape of epilepsy management has become more complex with the introduction of these newer agents.

Purpose:

• To review the nine new antiepileptic drugs launched since 1990 in France.
• To assess the evolving indications and therapeutic positioning of these novel AEDs.
• To analyze the safety, efficacy, and limitations of these new antiepileptic molecules.

Summary:

• New antiepileptic drugs like vigabatrin, felbamate, gabapentin, lamotrigine, tiagabine, fosphenytoin, topiramate, oxcarbazepine, and levetiracetam have been introduced.
• Indications are expanding, including first-line monotherapy for certain seizure types in adults and children.
• However, some drugs have restricted use due to severe side effects, and others show variable efficacy/safety profiles, with some potentially worsening epilepsy symptoms.

Impact:

• The availability of new AEDs has broadened epilepsy treatment but complicated clinical management.
• While effective for moderate epilepsy, their impact on severe epilepsy remains limited.
• Further rigorous clinical trials are necessary to define specific indications, especially in pediatric populations, and to explore surgical and alternative approaches.